Newsletter | March 29, 2023

03.29.23 -- Decide Your Product Strategy: Allogeneic vs. Autologous Cell Therapy

The Future Of Plasmid DNA Upstream Optimization

The advancement of messenger RNA (mRNA) vaccines and viral vector-based gene therapies has fueled the growth opportunity for the plasmid DNA (pDNA) market. An optimized upstream manufacturing process is crucial for producing the necessary amount of pDNA required for therapeutic and vaccine applications.

Allogeneic Vs. Autologous Cell Therapy: Deciding On Your Product Strategy

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs. Discover a few considerations that developers should keep in mind as they design their next cell therapy treatment.

The Promise Of NK Cells And 3 Strategies For Creating A Cost-Effective Program

For companies creating NK cell therapy treatments, one of the biggest challenges is the cost, as advanced therapies continue to be more expensive to produce than traditional large molecule therapies. Explore three strategies for creating a cost-effective NK cell biopharma product.

Adherent Versus Suspension Processes For Viral Vector Manufacturing

When addressing the question of commercial viability, drug developers face a crucial question of which manufacturing process is better. In adherent cell culture, cells are grown while attached to a substrate as monolayers, while in suspension cell culture, cells are free floating in the culture medium. Which offers more benefits?

Producing Customized Viral Vectors That Respond To Market Demands

Plug and play platforms can be adapted to different therapeutic genes without starting the development from scratch for each product, making the transfer to GMP as fast and smooth as possible. This approach offers flexibility and the possibility to replace the GFP gene with any therapeutic genes through a simple cut-and-sew cloning strategy.

Cell Therapy Capabilities

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. Our teams of scientists have 30 years of cell therapy development, manufacturing, and regulatory experience, including bringing three commercial products to market.

Request Information
Viral Vector Capabilities

AGC Biologics scientists have three decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). We develop and manufacture viral vectors that meet clinical and commercial demands for gene therapy products.

Request Information